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The HER2-enriched (HER2-E) subtype within HER2-positive (HER2+) breast cancer is highly
addicted to the HER2 pathway. However, ∼20–60% of HER2+/HER2-E tumors do not
achieve a complete response following anti-HER2 therapies. Here we evaluate gene
expression data before, during and after neoadjuvant treatment with lapatinib and trastu-
zumab in HER2+/HER2-E tumors of the PAMELA trial and breast cancer cell lines. Our
results reveal that dual HER2 blockade in HER2-E disease induces a low-proliferative Luminal
A phenotype both in patient’s tumors and in vitro models. These biological changes are more
evident in hormone receptor-positive (HR+) disease compared to HR-negative disease.
Interestingly, increasing the luminal phenotype with anti-HER2 therapy increased sensitivity
to CDK4/6 inhibition. Finally, discontinuation of HER2-targeted therapy in vitro, or acquired
resistance to anti-HER2 therapy, leads to restoration of the original HER2-E phenotype. Our
findings support the use of maintenance anti-HER2 therapy and the therapeutic exploitation
of subtype switching with CDK4/6 inhibition.
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Breast cancer consists of four molecular intrinsic subtypes(i.e., Luminal A, Luminal B, HER2-enriched [HER2-E] andBasal-like) and a normal-like group1–5. Among them, the
HER2-E is characterized by high expression of growth factor
receptor-related genes (ERBB2, EGFR and/or FGFR4) and cell
cycle-related genes, low expression of estrogen-related genes such as
ESR1 and PGR, and low expression of basal-related genes6.
Although the HER2-E subtype is related to HER2+ disease as
defined by immunohistochemistry, important discrepancies exist
and HER2-E subtype represents ∼60%, ∼80% and ∼40% of
HER2+, HER2+/hormone receptor-negative (HER2+/HR-nega-
tive) and HER2+/HR+ tumors, respectively7.
The clinical value of the HER2-E subtype in HER2+ breast
cancer is starting to be elucidated. From a therapeutic perspective,
the HER2-E subtype has shown, across 14 clinical trials and
∼2,000 patients, higher sensitivity to anti-HER2-based therapies
than the non-HER2-E subtypes7–20. However, not all HER2-E
tumors achieve a complete response following anti-HER2-based
therapies. For example, the pathological complete response (pCR)
rates in HER2-E subtype following anti-HER2-based neoadjuvant
therapy, with or without chemotherapy, are 40–80%21. At the
same time, HER2-E tumors that do not achieve a pCR have a
poor survival outcome22. Thus, there is a need to better under-
stand the biology associated with incomplete response to HER2-
targeted therapy in HER2-E disease. Here, we study patient’s
tumor samples and preclinical models before, during and after
anti-HER2 therapy to shed light on this clinical observation.
Results
Early in vivo biological changes during dual HER2 blockade.
To identify early molecular changes induced by dual HER2
blockade in patients with HER2-E disease, gene expression pro-
filing was performed in 96 tumor samples obtained before and
at day 14 of treatment with lapatinib and trastuzumab (and
endocrine therapy if the tumor was HR+) in the PAMELA
phase II clinical trial7. The expression of the 50 PAM50 genes and
6 signatures (Basal-like, HER2-E, Luminal A, Luminal B, normal-
like and the 11-gene proliferation score) was explored at
both time-points (Fig. 1a). Among the 56 variables, 85.7% and
94.7% were found differentially expressed (False Discovery Rate
[FDR]<5%) in HR+ (n= 35) and HR-negative (n= 61) disease,
respectively (Supplementary Table 1). The magnitude of expres-
sion of the transcriptional profiles in HER2+/HR+/HER2-E and
HER2+/HR-negative/HER2-E disease was strongly correlated
(Pearson correlation coefficient= 0.93, P-value (p) < 0.001)
(Supplementary Fig. 1a). Overall, a significant relative increase in
Luminal A and normal-like signature scores, and a relative
decrease in proliferation, HER2-E and Luminal B scores, was
observed at day 14 compared to baseline (Fig. 1b). Although
similar biological changes were observed in HER2+/HR+/HER2-
E and HER2+/HR-negative/HER2-E diseases, a PAM50 subtype
switch from HER2-E to Luminal A was observed in 31.6% of
HR+ tumors and 4.8% of HR-negative tumors (Fig. 1c). The
observed shift to Luminal A subtype was due to a decrease in cell
proliferation-related genes and a significant increase in the
expression of luminal-related genes. Concordant with this find-
ing, Ki67 positivity by immunohistochemistry, determined in
tumor cells at day 14 (Supplementary Fig. 1b), was lower in
PAM50 Luminal A tumor samples compared to PAM50 non-
Luminal A tumor samples (mean Ki67 of 10.8% vs. 19.8%; p=
0.009 by two-tailed unpaired t-test). Of note, normal tissue
contamination at day 14 did not differ between PAM50 Luminal
A tumor samples compared to PAM50 non-Luminal A tumor
samples (mean tumor cellularity of 39.8% vs. 41.2%; p= 0.839 by
two-tailed unpaired t-test) (Supplementary Fig. 1c). Finally, since
patients with HER2+/HR+ disease in the PAMELA trial received
anti-HER2 therapy in combination with letrozole or tamoxifen,
and treatment with letrozole alone for 2 weeks has shown to
reduce Ki67 in HER2+/HR+ tumors in the PER-ELISA phase II
trial, specially within Luminal A and B disease10, we separated
and compared the gene expression changes at day 14 in the
PAMELA trial of HER2+/HR+/Luminal A or B tumors (n= 38)
with HER2+/HR+/HER2-E tumors (n= 38). The
analysis revealed a strong correlation (Pearson correlation
coefficient= 0.89, p < 0.001) between both gene lists, suggesting
that anti-HER2 therapies have a higher impact on molecular
tumor changes at day 14 than endocrine therapy (Supplementary
Fig. 1d), although we cannot exclude an additive or a synergistic
effect between anti-HER2 therapy and endocrine therapy in this
group of patients.
Next, we assessed the expression of the 56 genes/signatures in
paired tumor samples from 36 patients with HER2+/HER2-E
disease recruited in the LPT109096 phase II clinical trial23,
where patients were treated for 2 weeks with either lapatinib,
trastuzumab or the combination. Among the 56 genes/
signatures, 85.7% were found differentially expressed (Supple-
mentary Table 2). As expected, the gene expression profiles of
the LPT109096 and PAMELA trials were strongly correlated
(Pearson correlation coefficient= 0.87, p < 0.001) (Supplemen-
tary Fig. 2a). When each single arm was evaluated, no major
differences were observed, although lapatinib seems to have
a greater impact on molecular changes than trastuzumab
(Supplementary Fig. 2b–e). However, the small sample size
within each arm did not allow formal statistical comparison. Of
note, intrinsic subtype switching was not observed in tumor
samples from the LPT109096 study, possibly due to the small
sample size of the combination arm (n= 8) or the lack of
endocrine therapy.
Early in vitro biological changes during dual HER2 blockade.
To further evaluate the effects of dual HER2 blockade, we per-
formed several experiments in 3 HER2+ breast cancer cell lines
(BT474, which is HR+, SKBR3 and HCC1954, which are HR-
negative) and 1 HER2-negative cell line (MCF7, which is HR+).
PAM50 subtyping of the 3 cell lines revealed that BT474, SKBR3
and HCC1954 are HER2-E and MCF7 is Luminal B (Supple-
mentary Fig. 3a). These in vitro models were treated with tras-
tuzumab, lapatinib (an EGFR/HER2 tyrosine kinase inhibitor
[TKI]), neratinib (a pan-HER TKI) or tucatinib (a HER2 TKI) as
single agents (Supplementary Fig. 3b, c) or in combination. As
expected, all anti-HER2 treatments evaluated reduced cell viability
in a dose-dependent manner in BT474 and SKBR3 (Fig. 2a and
Supplementary Fig. 3b, c) but not in HCC1954, which has a
mutation in PIK3CA that might confer resistance to anti-HER2
therapy24, or MCF7, which does not overexpress HER2 (Supple-
mentary Fig. 3d). Concordant with this observation, phosphor-
ylation of HER2 and phosphorylation of the survival kinase AKT
were reduced upon treatment in BT474 and SKBR3, demon-
strating successful pathway inhibition (Fig. 2b). Dual HER2
blockade arrested cell cycle at G1 (Supplementary Fig. 4a) and
reduced clonogenic potential (Supplementary Fig. 4b), consistent
with known roles of HER2 downstream signaling pathways25.
Next, we evaluated the PAM50 subtypes, genes and signature
scores in BT474 and SKBR3 cells before and after 72 h treat-
ment with different combinations of trastuzumab (10 µg ml−1)
and a TKI (given at the IC50 for each cell line). Regarding
individual PAM50 genes and signatures, 100% and 92.8% were
found differentially expressed in BT474 and SKBR3, respectively
(Supplementary Table 3), and the magnitudes of gene expression
profiles were strongly correlated between the two cell lines
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Fig. 1 HER2 blockade led to a Luminal A phenotype in HER2-E tumors. a Schematic representation of the workflow to identify differences in PAM50 gene
expression signatures in HER2-E tumors (n= 151) of the PAMELA trial between baseline and day 14 of treatment with lapatinib (L) plus trastuzumab (T) plus
endocrine therapy (ET) if HR+. b PAM50 signature scores in HER2+/HR+/HER2-E at baseline (left) and HER2+/HR-negative/HER2-E at baseline (right)
tumors treated with dual HER2 blockade at baseline and day 14. Each line represents a tumor sample. Increases are represented in red and decreases in
green. P-values (p) in a and b were determined by two-tailed paired t-tests. c Unsupervised hierarchical clustering across 35 paired HER2+/HR+/HER2-E at
baseline tumors and 61 paired HER2+/HR-negative/HER2-E at baseline tumors. Heatmaps show high (red) to low (green) expression of mRNAs in each
sample. The day of biopsy and molecular subtype calls of each sample are shown. Source data are provided as a Source Data file.
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(Pearson correlation coefficient= 0.75, p < 0.001) and the gene
expression profile of each cell line was moderately correlated
(Pearson correlation coefficients= 0.46–0.76, p < 0.001) with the
gene expression profiles obtained from PAMELA and LPT109096
(Supplementary Fig. 5a, b). Similar to patient’s tumor samples,
dual HER2 blockade in cell lines led to a significant relative
increase in Luminal A and normal-like signature scores, and
a relative decrease in proliferation, HER2-E, Luminal B and
Basal-like signature scores (Fig. 2c). Regarding PAM50 subtype
changes, a switch to Luminal A following dual HER2 blockade
was observed in BT474 (HER2+/HR+/HER2-E) but not in
SKBR3 (HER2+/HR-negative/HER2-E) (Fig. 2d). Overall, the
biological changes observed in our in vitro models recapitulated
the biological changes observed in patients with HER2-E tumors
treated with dual HER2 blockade.
Biological changes after dual HER2 blockade. We then sought
to better understand the biology of HER2-E tumors after treat-
ment with dual HER2 blockade. To approach this, we completed
PAM50 gene expression analysis in residual tumors of 57 patients
with HER2-E recruited in the PAMELA who received 18 weeks of
dual HER2 blockade (Fig. 3a). Of note, the median time from the
last dose of therapy to surgery, where the tumor samples were
obtained, was 29.5 days (range= 7–76 days). Among the 56
PAM50 genes and signatures, 92.8% were found differentially
expressed in residual tumors at surgery compared to day 14
(Supplementary Table 4). The vast majority of genes or signatures
(46/56, 82.1%) were found up-regulated at surgery compared to
day 14, including all proliferation-related genes (i.e., UBE2T,
EXO1, CDCA1, TYMS, CEP55, CDC20, UBE2C, or MKI67) and
the proliferation signature (Fig. 3b). Among the down-regulated
genes or signatures (10/56, 18%), we identified the Luminal A
signature (Fig. 3b). However, we did not observe a correlation
between the rebound effect and the number of days from the last
dose and the day of the surgical procedure (Supplementary Fig. 6).
Following these observations in patient’s tumors, we hypothe-
sized that discontinuation of dual HER2 inhibition reverts its
biological effects. Therefore, we evaluated the biological effects in
preclinical models after interrupting anti-HER2 treatment. BT474
and SKBR3 cells were treated with combinations of trastuzumab
and a single TKI for 72 h, treatment was then discontinued and
cells were cultured for another 72 h without treatment. Gene
expression analysis revealed a rebound effect in 75% and 100%
PAM50 genes and signatures in BT474 and SKBR3 respectively
after anti-HER2 therapy discontinuation (Supplementary
Table 5). We observed a significant relative decrease in Luminal
A and normal-like signature scores, and a significant relative
increase in Proliferation, Luminal B and Basal-like signature
scores in BT474 and SKBR3 cells (Fig. 3c). The gene expression
profiles of both cell lines were strongly correlated (Pearson
correlation coefficient= 0.69, p < 0.001). Finally, BT474 cell line
was identified by PAM50 as HER2-E as the parental cell line once
anti-HER2 therapy was withdrawn (Fig. 3d).
Biological changes during anti-HER2 resistance. To understand
the changes in molecular phenotypes induced by chronic HER2
inhibition, we established a BT474-derived lapatinib and trastu-
zumab resistant (BT474-LRTR) cell line and a BT474-derived
tucatinib and trastuzumab resistant (BT474-TuRTR) cell line. Cell
viability assays demonstrated that BT474-LRTR and BT474-
TuRTR cells were resistant to combinations of lapatinib plus
trastuzumab, or tucatinib plus trastuzumab, as opposed to par-
ental BT474 (Fig. 4a). BT474-LRTR and BT474-TuRTR were
cultured with 2 µg ml−1 trastuzumab and 2 nM of lapatinib or
tucatinib, respectively, concentrations at which the parental
BT474 became Luminal A. However, BT474-LRTR and BT474-
TuRTR remained HER2-E (Fig. 4b). We subsequently compared
the molecular profile of BT474-LRTR and BT474-TuRTR cell lines
with their parental HER2-E BT4T4 cell line. Among the 56
variables, 39.9% and 16.1% were significantly upregulated and
60.7% and 44.7% were significantly downregulated in BT474-
LRTR and BT474-TuRTR respectively. Both transcriptional pro-
files were highly correlated (Pearson correlation coefficient=
0.83, p < 0.001), with FGFR4 being the most upregulated gene
(Supplementary Table 6). Interestingly, FGFR4 is a known driver
of the HER2-E phenotype26. Finally, no differences were observed
between both resistant cell lines (i.e., BT474-LRTR and BT474-
TuRTR).
Dual HER2 inhibition and sensitivity to CDK4/6 inhibition.
Whether the shift to the Luminal A phenotype induced by dual
HER2 inhibition could sensitize HER2-E cell lines to highly
effective therapies in patients with luminal disease, such as CDK4/
6 inhibitors27–29, is unknown. To approach this, BT474 and
SKBR3 cells were treated for 24 h with either trastuzumab or a
single TKI to induce a Luminal A phenotype. HCC1954 was used
as a negative control, as it is intrinsically resistant to anti-HER2
treatments. Palbociclib was then added in combination with an
anti-HER2 treatment for 72 h. Surprisingly, BT474 and SKBR3
cells became more sensitive to palbociclib after being exposed to
anti-HER2 therapies, indicating that the acquisition of a more
luminal-like phenotype can sensitize cells to CDK4/6 inhibition.
As expected, anti-HER2 treatments did not increase sensitivity to
palbociclib in HCC1954. At the same time, both BT474-LRTR and
BT474-TuRTR cell lines were insensitive to palbociclib (Fig. 5a),
further demonstrating that the HER2-E phenotype is resistant to
anti-CDK4/6 treatments. Overall, this data suggested that anti-
HER2 treatment can modulate the sensitivity to CKD4/6 inhibi-
tion in HER2-E disease by inducing a Luminal A-like phenotype,
while cells that remain HER2-E (such as the BT474-derived
HER2-resistant cells) do not respond to these treatments (Fig. 5b).
As expected, anti-HER2 therapy reduced the expression levels of
Cyclin D1 and the phosphorylation of retinoblastoma (RB) and
the combination of HER2 and CDK4/6 inhibitors reduced the
phosphorylation of RB more than CDK4/6 inhibitor alone
(Fig. 5c). Concordant with this observation, dual HER2 block-
ade led to a decrease in CCND1 mRNA levels at week 2 in
HER2+/HR+ disease of the PAMELA trial (Fig. 5d). Altogether,
these data suggest that the combination is more efficient at
arresting cell cycle and preventing tumor growth (Fig. 5e).
Discussion
The HER2-E intrinsic molecular subtype has higher anti-HER2-
sensitivity compared to other molecular subtypes7–20. However,
the molecular and phenotypic characteristics of the HER2+/
HER2-E resistant tumors are not well understood. This is critical,
as 20–30% and 50–70% of patients with HER2+/HER2-E tumors
do not achieve a pCR following dual HER2 blockade with and
without chemotherapy, respectively.
Our main observation is that HER2-E tumors cells that are sen-
sitive to anti-HER2 therapy but do not die acquire a Luminal A
phenotype. This is especially relevant in HER2+/HR+ disease.
According to our results, the acquisition of this phenotype is rela-
tively rapid (i.e., 14 days in tumors and 72 h in cell lines) and leads
to anti-HER2 resistance. For example, HER2-E tumors that became
Luminal A at day 14 in the PAMELA trial7 had a 20% pCR rate
upon completion of the neoadjuvant treatment compared to 55.8%
in those HER2-E tumors that became normal-like, a biomarker of
tumor responsiveness and stromal contamination. This switch into a
Luminal A phenotype has also been reported following neoadjuvant
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Fig. 2 Effects of anti-HER2 treatments in HER2-E breast cancer cell lines. a Cell viability (%) of BT474 and SKBR3 cells upon treatment with increasing
concentrations of the TKI lapatinib, neratinib or tucatinib as monotherapy or in combination with 10 µgml−1 trastuzumab for 72 h. Data points represent the
mean; error bars represent the standard error of the mean of 3 independent experiments. b Phosphorylation and total levels of HER2 and AKT upon 24 h of
treatment with 10 µgml−1 trastuzumab plus TKI (10 nM lapatinib, 10 nM neratinib, 10 nM tucatinib) as assessed by Western Blot. c PAM50 signature scores
in BT474 and SKBR3 cells untreated and treated with combinations of TKI and trastuzumab for 72 h. Each line represents a paired sample. Increases are
represented in red and decreases in green. P-values (p) were determined by two-tailed paired t-tests. d Unsupervised hierarchical clustering using the
PAM50 genes across BT474 and SKBR3 cells treated with combinations of TKI and trastuzumab for 72 h. The heatmaps show high (red) to low (green)
expression of mRNAs in each sample. The molecular subtype call and treatment of each sample is shown. Source data are provided as a Source Data file.
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Fig. 3 Biological changes after dual HER2 blockade. a Schematic representation of the workflow to identify differences in PAM50 gene expression
signatures in HER2-E tumors at baseline of the PAMELA trial between day 14 of treatment and residual tumors. b PAM50 signature expression changes
between baseline, day 14 and surgery in 57 residual tumors at surgery. Each line represents a tumor sample. Increases are represented in red and
decreases in green. P-values (p) were determined by two-tailed paired t-tests. c PAM50 signature scores in BT474 and SKBR3 cells untreated, treated with
TKI+ trastuzumab for 72 h and upon treatment discontinuation for 72 h. Each line represents a paired sample. P-values (p) were determined by two-tailed
paired t-tests. d Unsupervised hierarchical clustering using the PAM50 genes across untreated BT474 cells, treated cells with combinations of TKI and
trastuzumab for 72 h and cells where treatment was removed for another 72 h. The heatmap shows high (red) to low (green) expression of mRNAs in each
sample. The molecular subtype call of each sample is shown.
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anti-HER2-based chemotherapy. In CALGB4060113, NeoSphere30
and NSABP B-4120 trials, 30–67% of HER2-E tumors became
Luminal A in residual disease. Not achieving a pCR after neoadju-
vant treatment is associated with poor event free survival and
overall survival in HER2+ breast cancer31. Altogether, these results
identify the Luminal A phenotype as a predictive biomarker of
resistance to anti-HER2 therapy.
Our study highlights two additional aspects. First, the subtype
switch seems reversible upon stopping anti-HER2 therapy. This
could explain why maintenance therapy with anti-HER2 therapy
both in the adjuvant and metastatic settings are beneficial to
patients, especially in high-risk patients32. Interestingly, a re-
bound effect after stopping treatment has also been seen with
other therapies such as CDK4/6 inhibitors28. Second, subtype
switching from HER2-E to Luminal A might open an opportunity
to treat the acquired phenotype with drugs that are known to be
active in Luminal A, such as endocrine therapy and/or CDK4/6
inhibitors. For example, the PATRICIA phase II trial29 in
advanced HER2+/HR+ disease revealed that the Luminal A
tumors had improved progression-free survival when treated with
palbociclib and trastuzumab as compared to HER2-E tumors. It is
important to note that patients in the PATRICIA trial had been
previously treated with a mean of 3 prior lines of anti-HER2-
based therapy. Thus, HER2-E tumors at this stage are likely to
have high anti-HER2 resistance and switching to a Luminal A
phenotype is unlikely. Although this is a hypothesis and needs
further validation, our preclinical data using HER2+ cell lines
with a complete resistance to anti-HER2 treatment supports this
observation.
The HER2 signaling pathway directly regulates the expression
of Cyclin D1, affecting its interaction with CDK433, this provides
a rationale for the concomitant HER2 and CDK4/6 inhibition in
patients. Indeed, combinations of anti-HER2 therapies with
CDK4/6 inhibitor and endocrine therapy are being investigated in
2 phase III trials for advanced HER2+/HR+ disease (i.e.,
PATINA34 and monarcHER35). Both trials differ in the popula-
tion being evaluated. PATINA focuses on maintenance therapy in
HER2+ tumors that are responding to anti-HER2 therapy,
whereas monarcHER35 focuses on tumors that have progressed to
at least 2 prior lines of anti-HER2 therapy. Concordant with our
hypothesis, the monarcHER main results presented at ESMO
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Fig. 4 Biological changes during anti-HER2 resistance. a Cell viability of BT474, BT474-derived lapatinib and trastuzumab resistant (BT474-LRTR) and
BT474-derived tucatinib and trastuzumab resistant (BT474-TuRTR) cells upon treatment with increasing doses of lapatinib+ /− 10 μgml−1 trastuzumab
or increasing doses of tucatinib+ /− 10 μg ml−1 trastuzumab, respectively. Data points represent the mean; error bars represent the standard error of the
mean of 3 independent experiments. (b) Unsupervised hierarchical clustering in BT474, BT474-LRTR and BT474-TuRTR treated with of 2 nM lapatinib plus
2 μg ml−1 trastuzumab or 2 nM tucatinib plus 2 μg ml−1 trastuzumab The heatmap shows high (red) to low (green) expression of mRNAs in each sample.
The molecular subtype call and treatment of each sample is shown. Source data are provided as a Source Data file.
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Fig. 5 Shift to Luminal A sensitizes cells to anti-CDK4/6 treatments. a Dose–response curve of BT474, SKBR3, HCC1954, BT474-derived lapatinib and
trastuzumab resistant (BT474-LRTR) and BT474-derived tucatinib and trastuzumab resistant (BT474-TuRTR) cells upon treatment with anti-HER2 drugs for
24 h and subsequent treatment with anti-HER2 plus increasing concentrations of palbociclib for 72 h. Surviving fraction was assessed by staining with
Hoechst 33342. Data points represent the mean; error bars represent the standard error of the mean of 3 independent experiments. b Schematic
representation of HER2-E breast cancer cells that are sensitive to dual HER2 blockade treatment, which triggers cell growth inhibition but also a shift to a
Luminal A molecular phenotype in residual cells. These changes are reversible after treatment discontinuation, while inhibition of HER2 improves sensitivity
to CDK4/6 targeted therapies. BT474 resistant to anti-HER2 treatments remain HER2-E and do not respond to inhibition of HER2 and CDK4/6. c Western
Blot assessing the phosphorylation of RB and the expression of Cyclin D1 in BT474 cells upon 24 h of treatment with 10 nM TKI (lapatinib, neratinib,
tucatinib), with 10 µgml−1 trastuzumab, with the combination of TKI plus trastuzumab, 10 nM palbociclib or with the combination of palbociclib with anti-
HER2 treatments, and in BT474-LRTR and BT474-TuRTR treated with 2 µgml−1 trastuzumab+ 2 nM TKI (lapatinib and tucatinib respectively) with or
without palbociclib. (d) CCND1 mRNA levels in HER2+/HR+ tumors of the PAMELA trial at baseline and day 14. Each line represents a paired sample.
Increases are represented in red and decreases in green. P-value (p) was determined by two-tailed paired t-tests. (e) Schematics of the mechanism by which
double-targeting the HER2 and CDK4/6 pathways can prevent RB phosphorylation and arrest cell cycle. Source data are provided as a Source Data file.
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superior to chemotherapy+ trastuzumab (Hazard ratio= 0.67;
p= 0.025; 8.3 vs. 5.7 months) most likely due to the luminal
tumors deriving larger benefit form CDK4/6 inhibition and
endocrine therapy compared to chemotherapy.
Our study has two limitations worth noting. First, although a
switch from HER2-E to Luminal A has been described after
combinations of trastuzumab, pertuzumab and chemotherapy in
clinical samples13,37, we have not explored the molecular effects
in vitro of dual HER2 blockade with trastuzumab and pertuzu-
mab, as our in vitro models cannot recapitulate antibody-
dependent cellular cytotoxicity. Second, although our preclinical
data suggest that a switch to Luminal A could be leveraged with
CDK4/6 inhibition, we do not have clinical evidence that patients
with HER2-E tumors that become Luminal A upon anti-HER2
therapy benefit from CDK4/6 inhibitors. Further clinical studies
are needed to address this preclinical hypothesis.
In conclusion, our findings support the use of maintenance
anti-HER2 treatment in HER2+ breast cancer sensitive to anti-
HER2 therapies, and warrant further research into exploiting
molecular subtypes changes (i.e., HER2-E to Luminal) to improve
patient outcomes.
Methods
PAMELA study. The main results of the PAMELA neoadjuvant phase II study
have been previously reported7. This study is registered with ClinicalTrials.gov,
number NCT01973660, and it is completed. The study protocol was approved by
independent ethics committees at each center. In this trial, 151 patients with early
HER2+ breast cancer were treated with neoadjuvant lapatinib (1000 mg daily) and
trastuzumab (8 mg kg−1 i.v. loading dose followed by 6 mg kg−1) for 18 weeks.
Patients with HR+ breast cancer received letrozole or tamoxifen according to
menopausal status. Tumor samples were collected at baseline, day 14 and surgery
and subsequently formalin-fixed paraffin-embedded (FFPE). As previously repor-
ted7, Ki67 was evaluated by IHC on FFPE tissue sections from core biopsies at
baseline and at day 14 of treatment. These data are provided as a Source Data file.
LPT109096 study. The main results of the LPT109096 neoadjuvant phase II study
have been previously reported23. This study is registered with ClinicalTrials.gov,
number NCT00524303. In this trial, 100 patients with early HER2+ breast cancer
were randomized to lapatinib, trastuzumab or both. Patients received 2 weeks of
treatment without chemotherapy, and after a tumor biopsy, they received the same
anti-HER2 treatment in combination with chemotherapy consisting of 5FU 500
mgm−2+ epirubicin 75 mgm−2+ cyclophosphamide 500 mgm−2 i.v. every
21 days (FEC75) for four cycles followed by weekly paclitaxel 80 mgm−2 for
12 weeks. Trastuzumab was administered every week (4 mg kg−1 i.v. loading dose
followed by 2 mg kg−1). Lapatinib was administered every day (1250 mg if given
without chemotherapy, 750 mg during FEC75 and 1000 mg during paclitaxel).
Tumor samples were collected at baseline and day 14 and subsequently FFPE
according to protocol.
Cell lines and drugs. The breast cancer cell lines BT474, SKBR3 and MCF7 were
purchased from the American Type Culture Collection (ATCC, Manassas, VA,
USA). All cell lines were maintained as recommended by the suppliers. All cell lines
were authenticated using Human 9-Marker STR Profile and Interspecies Con-
tamination Test by IDEXX BioAnalytics. Lapatinib, neratinib, tucatinib and pal-
bociclib were purchased from Selleckchem (Houston, TX, USA). Trastuzumab was
obtained from Roche Farma (Basel, Switzerland). A BT474-derived lapatinib and
trastuzumab resistant (BT474-LRTR) cell line and a BT474-derived tucatinib and
trastuzumab resistant (BT474-TuRTR) cell line were established by treating BT474
with the corresponding TKI plus trastuzumab for 6 months, starting at low con-
centrations and increasing them at each passage. BT474-LRTR are maintained with
2 nM lapatinib+ 2 µg ml−1 trastuzumab, while BT474-TuRTR are maintained with
2 nM tucatinib+ 2 µg−1 ml trastuzumab.
RNA extractions. RNA samples of the PAMELA trial from baseline and day 14 of
treatment were previously extracted as reported7. Here, we extracted RNA from 57
residual surgical tumor FFPE material (non-pCR) from the PAMELA trial and 36
pairs of FFPE tumor samples (baseline and day 14) from the LPT109096 study
using the High Pure FFPET RNA isolation kit (Roche, Indianapolis, IN, USA)
following manufacturer’s protocol. At least 1–5 10 μm FFPE slides were used for
each tumor specimen, and macrodissection was performed to avoid contamination
with normal breast tissue if needed. The RNeasy Mini Kit (Qiagen, Hilden,
Germany) was used to extract RNA from cell lines plated in triplicates in 6-well
plates at a density of 150,000 cells per well. RNA was quantified at the NanoDrop
spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).
Gene expression analysis. RNA samples of the PAMELA trial from HER2-E
tumors at baseline (n= 101) and day 14 of treatment (n= 96) were previously
analyzed7. Here, the nCounter platform (NanoString Technologies, Seattle,
Washington, USA) analyzed RNA samples from 57 residual tumors from the
PAMELA trial, RNA from 36 paired tumors from the LPT109096 study, and RNA
from cell lines treated with anti-HER2 and anti-CDK4/6 therapies. A minimum of
100 ng of total RNA was used to measure the expression of 50 genes of the PAM50
intrinsic subtype predictor assay and 5 housekeeping genes (ACTB, MRPL19, PSMC4,
RPLP0 and SF3A1). Expression counts were then normalized using the nSolver
4.0 software and custom scripts in R 3.4.3. For each sample we calculated the
PAM50 signature scores (Basal-like, HER2-E, Luminal A and B, normal-like) and the
proliferation signature score38. These data are provided as a Source Data file.
Cell viability assays. Cells were plated in triplicate at 4000 cells per well in 96-well
plates. The day after seeding, cells were treated with increasing concentrations of
TKI (lapatinib, neratinib and tucatinib) and 10 µg ml−1 trastuzumab. Cell viability
was determined 72 h after treatment using CellTiter 96 AQueous One Solution Cell
Proliferation Assay (MTS) (Promega Corporation, Madison, Wisconsin, USA)
following the manufacturer’s instructions, and quantified using the Gen5 Micro-
plate Reader and Imager Software (BioTek, Winooski, Vermont, USA). For anti-
CDK4/6 treatments, cells were plated in triplicate at 4000 cells per well in 96-well
plates and treated at low doses of TKI or DMSO for 24 h. Cells were then treated
with increasing concentrations palbociclib in combination with low doses of TKI or
DMSO. At 72 h, cells were labeled with the DNA stain Hoechst 33342 (Invitrogen,
Life Technologies, Paisley, UK) and fluorescence was subsequently determined at
the Gen5 Microplate Reader and Imager Software. GraphPad Prism was used for
statistics. These data are provided as a Source Data file.
Western blotting. Cells were plated in triplicate at 150,000 cells per well in 6-well
plates and treated with TKI and trastuzumab. Cell lysates were collected after 24 h of
treatment with Pierce RIPA buffer (Thermo Fisher Scientific, Waltham, MA, USA)
supplemented with protease inhibitors: 5 µM NaF, 1 µM PMSF, 1 µM Na3O4V, 1 µM
benzamidine, 1 µgml−1 aprotinin, 1 µM leupeptin, 1 µM DTT. Total protein extracts
were quantified using the DC Protein Assay (BioRad Laboratories, Hercules, Cali-
fornia, USA). 25 μg of proteins were separated in reducing conditions (2.5% β-
mercaptoethanol) by SDS–PAGE and transferred to nitrocellulose membranes
(BioRad Laboratories, Hercules, California, USA) for further processing, following
standard Western blotting procedures. Primary antibodies used in this study were:
HER2 (D8F12), Phospho-HER2 (Tyr1221/1222) (6B12), AKT, Phospho-Akt
(Ser473) (D9E), Phospho-RB (Ser807/811) (D20B12), Cyclin D1 (92G2) and anti-
GAPDH (14C10) rabbit antibodies from Cell Signaling Technologies (Massachusetts,
USA). The secondary fluorescent antibody used was the IRDye 800CW Donkey anti-
Rabbit IgG (LI-COR Biosciences, Lincoln, Nebraska, USA). Fluorescent signal was
acquired by the Odyssey Imaging System (LI-COR Biosciences, Lincoln, Nebraska,
USA). Uncropped blots are provided as a Source Data file.
Cell cycle analysis. BC cell lines were fixed in 70% cold ethanol after 72 h of
treatment with combinations of 10 µg ml−1 trastuzumab and TKI (10 nM lapatinib,
2 nM neratinib or 10 nM tucatinib) or with DMSO control. Propidium Iodide (PI)
was used to stain total DNA. Data acquisition was performed at the Cytometry and
cell sorting core facilities of the Institut d’Investigacions Biomèdiques August Pi i
Sunyer (IDIBAPS) using a BD FacsDiva analyzer. GraphPad Prism was used for
statistics. These data are provided as a Source Data file.
Clonogenic assay. Breast cancer cell lines were plated at low density in 6-well
plates and treated with combinations of 10 µg ml−1 trastuzumab and TKI (10 nM
lapatinib, 2 nM neratinib or 10 nM tucatinib) or with DMSO control. After 10 days,
cells were fixed with cold methanol and stained with 0.5% crystal violet solution.
Statistical analysis. To identify genes and signatures whose expression was sig-
nificantly different between paired samples (baseline vs day 14 or day 14 vs. surgery
for clinical samples, or untreated vs treated for cell lines) or unpaired samples
(parental cell lines vs anti-HER2 resistant cell lines) we used two-class paired Sig-
nificance Analysis of Microarrays (SAM) with a false discovery rate (FDR) <5%. All
statistical tests were two sided, and the statistical significance level was set to <0.05.
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying Figs. 1b, c, 2a–d, 3b–d, 4b, 5a, and Supplementary Figs. 1c,
3a–d, 4a and 6 are provided as a Source Data file, and are also available from the
corresponding author upon reasonable request.
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